Hwan Geun Choi

USPTO Granted Patents = 51 (Patent Applications = 9)

CIPO Patents = 5 (Patent Applications = 2)

EPO Patents = 8 (Patent Applications = 18)

Average Co-Inventor Count = 5.5

ph-index = 9

Forward Citations = 299(Granted Patents)

Forward Citations (Not Self Cited) = 243(Oct 12, 2025)

Location History:

Seoul, KR (2012 - 2022)
Chestnut Hill, MA (US) (2015 - 2023)
Daegu, KR (2019 - 2023)

Company Filing History:

32 out of 1,206

Dana-farber-cancer Institute Inc.

patents

11 out of 2,164

Korea Institute of Science and Technology

patents

5 out of 2,882

The General Hospital Corporation

patents

4. 4 out of 443

The Broad Institute, Inc.

patents

5. 4 out of 7

Daegu-gyeongbuk Medical Innovation Foundation

University Court of the University of Dundee

patents

8. 2 out of 321

Korea Research Institute of Bioscience and Biotechnology

patents

9. 2 out of 63

Hanmi Science Co., Ltd.

patents

10. 1 out of 623

Korea Research Institute of Chemical Technology

Daegu Gyeongbuk Institute of Science and Technology

patents

14. 1 out of 146

Hanmi Pharm. Co., Ltd.

National Cancer Center

patents

17. 1 out of 122

Samsung Life Public Welfare Foundation

patents

18. 1 out of 54

Catholic University Industry Academic Cooperation Foundation

patents

where one patent can have more than one assignee

Years Active: 2012-2025

Loading Chart...

51 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12331037 - Pyrimidines as EGFR-inhibitors and methods of treating disorders (2025-06-17),

2. 12157730 - Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component (2024-12-03),

3. 12152021 - Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component (2024-11-26),

4. 11826365 - Type II raf kinase inhibitors (2023-11-28),

5. 11725011 - Bicyclic urea kinase inhibitors and uses thereof (2023-08-15),

6. 11673882 - Pyrimidines as EGFR inhibitors and methods of treating disorders (2023-06-13),

7. 11466000 - Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component (2022-10-11),

8. 11447480 - Compound exhibiting enteropeptidase inhibitory activity (2022-09-20),

9. 11285158 - Uses of pyrimidopyrimidinones as SIK inhibitors (2022-03-29),

10. 11241435 - Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis (2022-02-08),

11. 11208412 - Pyrrolo-pyrimidine derivative compound, preparation method therefor, and pharmaceutical composition comprising same compound as effective ingredient for preventing or treating protein kinase-related disease (2021-12-28),

12. 11117892 - Pyrrolo-pyridine derivative compound, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of protein kinase-related diseases (2021-09-14),

13. 10975058 - Imidazolyl kinase inhibitors and uses thereof (2021-04-13),

14. 10954242 - Bicyclic urea kinase inhibitors and uses thereof (2021-03-23),

15. 10913744 - LRRK2 inhibitors and methods of making and using the same (2021-02-09),

As an AI assistant specialized in innovations, inventions, inventors, patent attorneys, assignees, and patents, I can provide you with a detailed article about inventor Hwan Geun Choi based on the data you have provided. Here is the structured article:

Title: The Innovations and Impact of Inventor Hwan Geun Choi

Introduction:

Hwan Geun Choi, a prolific inventor hailing from Seoul, South Korea, has garnered recognition for his groundbreaking work in the field of pharmaceuticals and kinase inhibitors. With an impressive portfolio of 48 patents to his name, Choi has made significant contributions to the medical industry through his innovative research and discoveries.

Latest Patents:

Choi's latest patents showcase his expertise in developing novel compounds for the treatment of various diseases. One of his recent inventions includes Type II Raf kinase inhibitors, focusing on modulating B-raf kinases to address a range of medical conditions. Additionally, his work on bicyclic urea kinase inhibitors demonstrates the potential to inhibit protein kinases like SIK, offering new possibilities for treating a diverse array of diseases and disorders.

Career Highlights:

Throughout his career, Hwan Geun Choi has made substantial strides in his field, primarily working with esteemed organizations such as the Dana-Farber Cancer Institute Inc. and the Korea Institute of Science and Technology. His dedication to research and development has paved the way for innovative pharmaceutical solutions that have the potential to revolutionize the healthcare industry.

Collaborations:

Choi's collaborative efforts with accomplished coworkers, including Nathanael Schiander Gray and Tae Bo Sim, have further enriched his contributions to the scientific community. By working alongside talented individuals, he has been able to exchange ideas, drive innovation, and push the boundaries of scientific discovery.

Conclusion:

In conclusion, Hwan Geun Choi stands out as a visionary inventor whose relentless pursuit of excellence has led to the creation of groundbreaking pharmaceutical compounds and kinase inhibitors. His impact on the field of medicine is undeniable, and his patents serve as a testament to his ingenuity and commitment to improving healthcare solutions for individuals worldwide.

This text is generated by artificial intelligence and may not be accurate.